Podcasts about Chief scientific officer

“We became an analytical powerhouse before we started offering integrated process development and manufacturing. That's what differentiates us.”Sigma Mostafa, Chief Scientific Officer, and Katie Edgar, Chief Business Officer at KBI Biopharma, explain how technical depth in analytics and proprietary cell line technology create competitive advantage in an increasingly crowded CDMO market.Sigma brings 15 years of experience with KBI, joining as Director of Process Development in 2010 and advancing through the company's exponential growth. Katie leads business strategy, focusing on long-term partnerships and proactive risk mitigation for customers ranging from virtual biotech startups to global pharmaceutical companies.In this PharmaSource podcast recorded live at CPHI Frankfurt 2025, Sigma and Katie reveal how KBI's analytical foundation, combined with high-touch customer relationships and digital integration tools, supports molecules from early development through commercial manufacturing.Full article

What if you could identify every structural variant in your biologics—without ambiguity, without massive sample requirements, and without the guesswork that plagues traditional mass spectrometry? Cryogenic infrared ion spectroscopy (CIRIS) makes it possible, transforming molecular characterization from frustrating puzzle to precise science.Today's guest, Professor Tom Rizzo, bridges the gap between academic innovation and industrial application. As former Dean of the School of Basic Sciences at EPFL in Lausanne and now Chief Scientific Officer at Isospec Analytics, Tom has spent over two decades developing analytical techniques that solve problems conventional methods can't touch.His journey from a childhood fascination sparked by chemistry demonstrations at the 1964 New York World's Fair to pioneering a breakthrough technology reveals both the persistence required for true innovation and the pathway from laboratory curiosity to commercial reality. For bioprocess scientists struggling with glycan characterization, isomer identification, or any structural puzzle where mass spec alone falls short, this conversation offers both validation and solutions.Episode Highlights:The fundamental limitations of current biomolecular analysis methods and why innovation is critical (02:51)From World's Fair chemistry demos to laser spectroscopy: Tom Rizzo's path to analytical innovation (03:31)The two-decade quest to combine mass spectrometry sensitivity with laser spectroscopy precision—and the machine that finally made it work (04:26)Why Tom transitioned from academic leadership to Isospec Analytics: bringing lab techniques to production environments (09:17)CIRIS fundamentals: how cooling ions to 10 Kelvin unlocks molecular fingerprints that room-temperature methods miss (11:14)CIRIS advantages for biologics: single-ion sensitivity, isomer discrimination, and unique molecular "fingerprints" for definitive identification (14:25)Integrating CIRIS into existing bioprocess workflows: LC-MS compatibility and the path to commercial instrumentation (17:29)Hard-won lessons from translating academic breakthroughs into industrial tools (17:43)When mass spectrometry hits its limits—distinguishing isomers, characterizing glycans, identifying unknowns in complex mixtures—cryogenic infrared ion spectroscopy provides the structural resolution you need. This isn't incremental improvement; it's a fundamental expansion of what's analytically possible.If you're facing molecular identification challenges that conventional methods can't solve, or if you're curious how next-generation analytical techniques will transform bioprocess development, this episode delivers actionable insights from a scientist who's lived both the innovation and implementation journey.Connect with Tom Rizzo:LinkedIn: www.linkedin.com/in/thomas-rizzo-4a0a6314/Contact email: tom@isospec.chIsospec Analytics website: www.isospecanalytics.comNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Cognitive decline is one of the most urgent health challenges of our time. People are experiencing memory lapses, brain fog, and attention problems earlier than ever before, yet early detection remains one of the biggest obstacles in dementia care. What can neuroscience teach us about protecting the aging brain?In this episode of The Aging Well Podcast, Dr. Jeff Armstrong is joined by Dr. Adrian Owen, world-renowned neuroscientist, co-founder and Chief Scientific Officer at Creyos, and bestselling author of Into the Gray Zone. Professor Owen's pioneering research on the brain, memory, and consciousness has transformed how we understand cognitive health and aging.Together, they explore the surprising science of memory and sleep, the importance of tracking brain function over time, and how early detection could reshape the future of dementia care. This conversation sheds light on what it means to protect our minds as we grow older—and how we can all take steps to… age well.Learn more about Creyos at https://creyos.com/Please, support The Aging Well Podcast by hitting the ‘like' button, subscribing/following the podcast, sharing with a friend, and….BUY the products you need to… age well from our trusted affiliates and support the mission of The Aging Well Podcast*.The Aging Well Podcast merchandise | Show how you are aging well | Use the promo code AGING WELL for free shipping on orders over $75 | https://theagingwellpodcast-shop.fourthwall.com/promo/AGINGWELLAuro Wellness | Glutaryl—Antioxidant spray that delivers high doses of glutathione (“Master Antioxidant”) | 10% off Code: AGINGWELL at https://aurowellness.com/agingwellpodcastRebalance Health | products created by hormone health experts to lower cortisol, improve sleep, and minimize the impact of stress on the body and mind | https://rebalancehealth.com with the promo code: AGINGWELLBerkeley Life | Optimize nitric oxide levels | Purchase your starter kit at a 15% discount | Use the promo code: AGINGWELL15 | https://berkeleylife.pxf.io/c/6475525/3226696/31118Oxford Healthspan | Primeadine®, a plant-derived spermidine supplement | 10% off code: AGINGWELL | https://oxford-healthspan.myshopify.com/AgingWellJigsaw Health | Trusted supplements. “It's fun to feel good.” | Click the following link for 10% off: https://www.jigsawhealth.com/?rfsn=8710089.1dddcf3&utm_source=refersion&utm_medium=affiliate&utm_campaign=8710089.1dddcf3Prolon | The Fasting Mimicking Diet (FMD) is a revolutionary five-day nutrition program scientifically formulated to mimic the effects of a prolonged water fast while still allowing nourishment - supporting the benefits of fasting without the challenges and risks that come from water-only fasts. | For the best available discount always use this link: https://prolonlife.com/theagingwellpodcastL-Nutra Health | The medical division of L-Nutra, focused on helping people manage and potentially reverse chronic health conditions, like type 2 diabetes, prediabetes, insulin resistance, and obesity, using personalized, lifestyle-based programs grounded in evidence, not prescriptions. | Use this link: https://l-nutrahealth.com/theagingwellpodcastThrive25—Your personal longevity advisor | https://www.thrive25.com/early-access?via=william-jeffreyFusionary Formulas | Combining Ayurvedic wisdom with Western science for optimal health support. | 15% off Code: AGINGWELL | https://fusionaryformulas.com?sca_ref=9678325.IHg5xYhdOzzke8Zr Dr Lewis Nutrition | Fight neurodegeneration and cognitive decline with Daily Brain Care by Dr Lewis Nutrition—a proven daily formula designed to protect and restore brain function. | 10% off code: AGINGWELL or use the link: https://drlewisnutrition.com/AGINGWELLTruDiagnostic—Your source for epigenetic testing | 12% off Code: AGEWELL or use the link: https://shop.trudiagnostic.com/discount/AGEWELL*We receive commission on these purchases. Thank you.

Ready to boost your energy and future-proof your health? In this episode, I'm joined by expert neuroscientist Dr. Siobhan Mitchell, who breaks down why your mitochondria—the tiny powerhouses inside your cells—are the secret to healthy aging.  She explains how the perimenopause and menopause transition is not just hormonal, but a neuroendocrine shift that impacts your brain, mood, energy, AND vitality.  And even if you're doing your best to bring on lifestyle recommendations for optimizing mitochondrial health, odds are you still need more support than just that in midlife. So, that's where the supplement MitoQ comes into play.  As MitoQ's Chief Scientific Officer, Dr. Mitchell reveals how this advanced antioxidant works deep inside your cells to enhance mitochondrial function, boosting mental clarity and long-term longevity.  Tune in and discover how to fuel your energy, elevate your mood, and embrace midlife feeling stronger than ever! Dr. Siobhan Mitchell  Siobhan Mitchell is the chief scientific officer of MitoQ. She completed her PhD at SUNY Albany and a post-doctoral fellowship on brain aging at the University of Washington. Siobhan has held roles at the three largest food companies in the world (Unilever, Nestle, and Pepsico), leading trials worldwide, which researched the effects of nutrition on cognitive decline, mood, and performance. She was also senior director at Noom, where she directed a team investigating chronic disease management, weight loss, and mental health digital programs using cognitive behavior therapy methods. IN THIS EPISODE Why mitochondria are a key contributing factor to aging  Preventing menopause symptoms in relation to brain changes  Research on estrogen levels in menopause for longevity  Lifestyle changes for enhanced cognitive functioning  The impact stress has on your mitochondrial function  How to notice if your mitochondria aren't working well  How MitoQ supplementation boosts cell vitality and longevity  Ways to measure your mitochondrial function  QUOTES“You get these overactive mitochondria that are also producing energy and oxidative stress at much higher levels, and these oxidative stress mechanisms can also bring on faster aging through inflammation and things like that.” “[MitoQ] is basically helping protect your mitochondria from excessive oxidative stress. It gets into the mitochondria better than any other supplement on the market because it was especially engineered to have this tag that allows it to get into the mitochondria up to [about] 90%.” RESOURCES MENTIONED Order my new book: The Perimenopause Revolution https://drmariza.com/book Use code DRMARIZA and get 15% off your order of Silverbiotics https://silverbiotics.com/discount/drmariza Use code: ENERGIZED for 10% off your order of MitoQ HERE! http://mitoq.com MitoQ on Instagram Siobhan on X  RELATED EPISODES  #688: Unlock Cellular Energy and Longevity with Urolithin A + Mitochondrial Optimization with  Jen Scheinman  #653: Mitochondria, Menopause & Metabolism: The Cellular Secret to More Energy After 40 with Dr. Felice Gersh #663: From Wired and Tired to Calm and Energized: The GABA-Mitochondria Connection + How to Fix It at the Cellular Level with Dr. Scott Sherr #623: Red Light Therapy for Upgrading Your Mitochondria, Cellular Energy, Skin and Brain Health with Jonathan Otto #690: The Perimenopause Revolution: Why midlife isn't the end — it's the beginning of your most energized, powerful, and vibrant self

AI and digital twins are redrawing the boundaries of drug discovery. Once defined by lab benches, animal studies, and years of trial and error, the field is now embracing virtual methodologies that promise faster, safer, and more precise innovation. But could these technologies ever make animal testing obsolete?In this episode of Tech Tomorrow, David Elliman speaks with Professor Julie Frearson, SVP and Chief Scientific Officer at Charles River Laboratories, about how artificial intelligence is transforming early-stage drug discovery. Julie explains how AI is already accelerating small-molecule design and enabling the use of virtual control animals, reducing the need for live testing without compromising scientific integrity.They also unpack the growing challenges of explainability, bias, and regulation in AI-driven science. From ensuring transparency and accountability in complex models to understanding how regulators like the FDA are beginning to accept hybrid data sets that combine in vivo results with AI predictions, the discussion balances optimism with realism in a rapidly evolving field.Ultimately, Professor Julie and David agree that while AI is reshaping discovery, humans must remain firmly in the loop. For now, it is the only way to ensure that innovation remains both ethical, trustworthy, and safe.Episode Highlights:01:31 – Areas of drug discovery already transformed by AI and digital twins.03:25 – Digital twins in animal testing and the creation of “virtual animals.”05:50 – David's thoughts: What executives often get wrong about digital twins.07:30 – How digital twins accurately recreate parts of animals.10:11 – How regulation currently views AI models in drug discovery.13:30 – The timeline for regulators to become more comfortable with hybrid data sets.14:37 – David's thoughts: How ‘black box' AI processes create challenges, and how to address them.16:31 – The role of humans in the drug discovery loop.17:37 – Will technology outpace regulation?20:34 – Could AI and digital twins make animal testing in drug discovery obsolete?About Zühlke:Zühlke is a global transformation partner, with engineering and innovation at its core. We help clients envision and build their businesses for the future – running smarter today while adapting for tomorrow's markets, customers, and communities.Our multidisciplinary teams specialise in technology strategy and business innovation, digital solutions and applications, and device and systems engineering. We thrive in complex, regulated sectors such as healthcare and finance, connecting strategy, implementation, and operations to help clients build more effective and resilient businesses.Links:Zühlke WebsiteZühlke on LinkedInDavid Elliman on LinkedInProfessor Julie Frearson on LinkedInCharles River Laboratories Website

In this science-backed and empowering episode of Resiliency Radio, Dr. Jill Carnahan is joined by Dr. Siobhan Mitchell, Chief Scientific Officer of MitoQ, to explore how optimizing mitochondrial health can revolutionize the way we age, perform, and heal. ⚡ Together, they unpack the critical role mitochondria play in everything from immune function and brain health to energy production, resilience, and mental well-being. Discover how MitoQ, a breakthrough antioxidant supplement, supports mitochondrial function, enhances athletic performance, and may even aid mental health and PTSD recovery by repairing cellular damage and reducing inflammation.

On this week's Tech Nation, Moira speaks withYou are smarter than you know - Dr. Angus Fletcher talks about Primal Intelligence, and then Dr. Derek Jantz from Tune Therapeutics explains how they aim to "tune" DNA - not just with human DNA, but stopping the Hepatitis B virus in its tracks.BTN Title: Tuning DNA, and Tuning Out Hepatitis BDr Derek Jantz, the Chief Scientific Officer of Tune Therapeutics, explains their approach, now in advanced clinical trials for Hepatitis B.

Greg's journey with LMNA cardiomyopathy, a rare inherited heart condition, began in high school when he experienced sudden episodes of rapid, irregular heartbeats during track practice. The cause remained a mystery for years, leading to misdiagnoses and untreated disease progression. During that time, Greg faced life-threatening arrhythmias and required several implanted devices before finally receiving a heart transplant. That experience, and the challenges that came before it, ultimately inspired his passion to create change and help others facing the same uncertainty. In this episode of On Rare, David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Senior Director of Patient Advocacy at BridgeBio, speak with Greg about the long road to diagnosis, the emotional impact of learning he had passed the condition on to his children, and his transformation into an advocate as president of the DCM Foundation. He also shares how his personal experience led to the launch of Everygene, a free genetic testing program for people with cardiomyopathies. Dr. Clayton Beard, Chief Scientific Officer at BridgeBio Gene Therapy, provides a high-level medical overview of LMNA-related dilated cardiomyopathy, a form of heart disease caused by mutations in the LMNA gene that compromise the structural integrity of heart cells and disrupt electrical signaling. He explains how these changes can cause dangerous arrhythmias, weaken the heart muscle, and lead to heart failure, making LMNA cardiomyopathy one of the most severe genetic forms of the condition. Dr. Beard also highlights the importance of early genetic testing for at-risk families, the role of research in improving detection and treatment, and how a better understanding of LMNA can lead to life-saving interventions.

Cell and gene therapies are transforming modern medicine, but their path to market is fast and complex. They often jump from small trials to global launch at record speed, putting pressure on analytics, supply chains, and partnerships. Success depends on making smart choices about what to build in-house and what to entrust to expert partners.Daniel Galbraith knows these challenges intimately. With decades of hands-on experience and as Chief Scientific Officer at Solvias, Daniel has witnessed firsthand the seismic shifts in analytical development for advanced therapies. He's been on every side of the table: troubleshooting manufacturing snags, scaling up from a single batch to hundreds per month, and guiding companies as they choose between in-house development and relying on a CRO's muscle.In this episode:How evolving cell and gene therapy timelines are driving the need for true CRO-drug developer partnerships (00:00)The unique challenges of scaling CMC analytics from early trials to global commercialization (02:51)Key pitfalls to avoid when outsourcing to CROs—especially around communication, scheduling, and troubleshooting (06:26)Deciding whether to build capabilities in-house or outsource to a CRO, and how to find the right balance for your team (08:41)The critical importance of strong project management for juggling relationships between developer, CRO, and CDMO (09:51)Daniel's perspective on the future of combination therapies and what the analytical landscape will demand of CROs (13:33)Practical advice for building transparent, open CRO partnerships that support your goals (15:21)Facing scale-up challenges or a first CGT launch? This conversation shares practical strategies to advance therapies efficiently.Tune in for actionable insights on CMC, outsourcing, and analytical development.Connect with Daniel Galbraith:LinkedIn: www.linkedin.com/in/daniel-galbraith-26a6138Solvias website: www.solvias.comEmail: daniel.galbraith@solvias.comNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callPreparing for your IND? Grab our Startup Founder CMC Dashboard in Notion to help you track tasks, timelines, and risks in one place at https://stan.store/SmartBiotech/p/discovertoind-cmc-dashboard-for-startup-founders

This conversation features insights from Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII. Our guests continue their discussion on how autoinjectors and smart technologies can be integrated into clinical trials in a way that isn't problematic or burdensome for patients, particularly for patients that may not be tech savvy. They discuss that by focusing on patient experience, clinical trials can increase engagement and compliance.This episode is presented in partnership with ⁠PII⁠.Host⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestsOliver Eden, Senior Business Unit Director, JabilTravis Webb, Chief Scientific Officer, PIIDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Carter Mitchell, Chief Scientific Officer at Kemp Proteins, brings scientific rigor and an artist's imagination to the world of protein design and production. In this episode, recorded at the Advanced Lateral Flow Conference, we explore how his company is pushing the boundaries of protein expression, quality, and analysis using tools that merge machine learning, automation, and human creativity.A company reborn through precision and innovationKemp Proteins has deep roots in recombinant protein production, tracing back over 30 years to a company that began with insect-cell expression systems. After a rocky acquisition phase, the company was revived with renewed focus under CEO Mike Keefe, this time with a modern quality management system and new emphasis on antibodies and engineering solutions for diagnostics, therapeutics, and vaccines.Carter, a self described protein nerd, joined around that time, bringing expertise in structural biology, protein engineering, and quantitative analytics and a mission to integrate AI into the company's core processes.Why insect cells still matterI knew that people used insect cells but I didn't know why. Mitchell explains how insect cells, long used in protein production, still offer unique advantages. Unlike E. coli, insect cells can perform post-translational modifications, such as glycosylation—key for producing proteins that resemble their natural human counterparts. While mammalian systems like HEK293 have since made expression “paint-by-numbers” simple, Carter notes that insect systems still excel when complexity and authenticity matter. “It's about having multiple expression capabilities,” he says, “so you can choose the right one for the problem at hand.”Four questions that guide every projectCarter's approach to solving client challenges starts with four questions:* What is the protein?* What information is available?* What's the intended use?* What's the scale?From there, the team tailors both the process and the system to ensure reproducibility and regulatory readiness, whether the goal is a diagnostic reagent or a therapeutic protein. As an aside, manufacturing kilograms of protein still blows my mind.As Carter puts it: “Regulators don't want to see a smear on an SDS page. We think like regulators, anticipate their questions, and design out variability before it becomes a problem.”From data lake to digital expert: ProtIQThe centerpiece of Carter's innovation is ProtIQ, an internal expert system that combines structured data, AI models, and domain expertise into a 200–300-page report for every target protein. Initially, these reports were for experts, but Carter's team is now transforming them into an interactive chatbot interface so anyone on the team can query the data conversationally.“If a technician can ask, ‘What's the isoelectric point?' or ‘Does it have a secretory tag?' and get an immediate answer, they're empowered,” he says.It's part of a broader effort to turn technicians into scientists, helping them engage more deeply with data, notice anomalies early, and contribute to process improvement.Predicting protein liabilities before they happenUsing sequence analysis and AI-assisted visualization, Kemp Proteins can predict potential degradation sites or stability issues before production even begins. Carter's team also models how viral variants like influenza strains might evolve over time, identifying changes in glycosylation patterns that could impact diagnostic binding. “We're actually collaborating with the FDA on this,” he adds.When science meets artCarter looks at protein structure like art. A lifelong painter and flamenco guitarist, he traces his fascination with structure to his mother's art studio and his childhood encounters with crystals in Texas soil. That visual mindset drives how he thinks about molecules: “Art flattens multi-dimensional space to describe motion. That's what we do in AI and machine learning, flattening complexity into something interpretable.” This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit cclifescience.substack.com

Finding an analytical CRO that's truly invested in your success, not just processing samples, makes all the difference in CMC development. In this episode, host David Brühlmann talks with Daniel Galbraith, Chief Scientific Officer at Solvias, about the essential questions and mindset that lead to breakthrough CRO partnerships.With nearly three decades in analytical development, spanning monoclonal antibodies, biosimilars, and cell and gene therapies, Daniel reveals what separates CROs who become true partners from those who just run methods. His insights can save your program months of delays and costly missteps.Key Topics Discussed:Why cell and gene therapies face unique challenges compared to the progression seen with monoclonal antibodies (03:04)Daniel's career path: from entering biotech in 1996 to CSO at Solvias, and the rapid evolution of the industry (05:00)The analytical hurdles in characterizing cell-based products and how their inherent variability impacts development (09:46)Approaches to analytical method requirements for autologous cell therapies, and how data is gathered iteratively in these cases (13:02)The biggest obstacles to scaling up cell and gene therapies, and why innovative cell manipulation technologies are needed (16:06)Current trends in therapeutic modalities: why antibody-drug conjugates stand out, and whether mRNA therapies are losing momentum (18:37)Practical advice on choosing an analytical CRO as a strategic partner - what to look for, what questions to ask, and why enthusiasm and standardization matter (21:55)Wondering how to streamline your own analytical strategy, or navigate the parallel universe of cell and gene therapy development? Dig into this episode for Daniel's insider perspective. Then consider how the right analytical partnership could accelerate your path to clinic.Connect with Daniel Galbraith:LinkedIn: www.linkedin.com/in/daniel-galbraith-26a6138Solvias website: www.solvias.comEmail: daniel.galbraith@solvias.comNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callPreparing for your IND? Grab our Startup Founder CMC Dashboard in Notion to help you track tasks, timelines, and risks in one place at https://stan.store/SmartBiotech/p/discovertoind-cmc-dashboard-for-startup-founders

What will the IVF lab look like in five years?Trying to predict and shape that response is Dr. Denny Sakkas, Chief Scientific Officer at Boston IVF and head of the scientific advisory board for AutoIVF.In this episode of Inside Reproductive Health, Dr. Sakkas about what automation really means for embryologists, and how new technologies could transform lab operations, chain of custody, and patient safety.Dr. Sakkas shares:– The potential downsides to automation and where caution is needed– How AutoIVF differs from AURA by Conceivable Life Sciences–  His prediction about time-lapse imaging within five years– The areas where embryologists must hold firm on lab standards– The next big innovations he's watching (and what Boston IVF plans to purchase next year)

In this episode of Two Bees in a Podcast, Amy Vu and Dr. Jamie Ellis discuss a new technology to control Varroa in Australia with Ron Korkidi, Chief Scientific Officer of ToBe Influencing Innovation. This episode ends with a Q&A segment. Check out our website: www.ufhoneybee.com for additional resources from today's episode. 

Facing unprecedented pressure from the Trump administration, some of the world's top drugmakers promise to cut prices. But experts say the savings might not be what they seem.Guests:Michael Cannon, Director of Health Policy Studies, Cato InstituteStacie Dusetzina, Professor of Health Policy, Vanderbilt UniversityDarius Lakdawalla, Chief Scientific Officer, USC Schaeffer CenterPete Loftus, Reporter, Wall Street JournalBen Rome, Assistant Professor of Medicine, Harvard Medical SchoolLeslie Walker, Senior Reporter, TradeoffsWe want to hear from you! Our audience survey takes less than ten minutes, and you'll be entered to win one of two $50 Bookshop.org gift cards.Learn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

An enlightening conversation with Dr. Robert Alexander, Chief Scientific Officer of the Alzheimer's Prevention Initiative at Banner Alzheimer's Institute, explores the cutting-edge world of Alzheimer's research and prevention. He takes us deep into the science behind one of medicine's most challenging frontiers. We dive into groundbreaking research studying autosomal dominant Alzheimer's disease. Dr. Alexander explains how scientists are unlocking the mysteries of amyloid processing in the brain by studying families genetically destined to develop the disease. Discover how this unique research approach is providing unprecedented insights into the earliest stages of Alzheimer's development and allows them to explore the promising therapeutic developments emerging from collaborative research efforts worldwide, including innovative drugs that target the disease at its source. 

On this week's Tech Nation, Moira speaks with University of Chicago professor, Dr. Marc Berman tells us about "Nature and the Mind   The Science of How Nature Improves Cognitive, Physical, and Social Well-Being." Then in biotech, Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, gives us the inside look on how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.

Solutions to manage PMS Guest Bio Somashekara Nirvanashetty, PhD, Co-Founder & Chief Scientific Officer, Olene Life Sciences Private Limited, is an accomplished biochemist with over 20 years of experience in pharmaceutical, nutraceutical, and agri-food innovation. He holds a PhD from Swinburne University of Technology, Australia, in collaboration with IIT-Madras. Dr. Somu has filed more than 45 patents, authored 10 peer-reviewed publications, and contributed to two book chapters.

Modern joint pain isn't just wear and tear—it's a systemic, metabolic disease that starts years before symptoms show. In this episode, you'll learn how inflammation, mitochondria dysfunction, and immune imbalance trigger cartilage loss… and how to reverse it using targeted cytokine modulation, cellular regeneration, and smarter supplements for longevity and human performance. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Kiran Krishnan, a research microbiologist and Chief Scientific Officer at Calroy Health Sciences. He's the founder of Microbiome Labs—one of the most trusted microbiome-focused brands in functional medicine—and a formulator behind cutting-edge supplements like Arterosil and Vascanox. With over two decades of experience, Kiran has launched multiple health ventures, authored scientific textbook chapters, published clinical trials, and holds global patents in human health. He's a leading authority on systemic inflammation, mitochondrial dysfunction, and gut-driven disease—and one of the few voices making complex biology accessible for real-world results. He breaks down their new supplement Cartigenix HP, and how cytokines like IL-6 and TNF-alpha flip your cartilage cells from anabolic repair to catabolic destruction, how mitochondrial decline speeds up joint damage, and why most modern painkillers make your joints worse. You'll learn how a specialized blend of boswellia and celery seed reprograms inflammation, why walking beats medication in clinical trials, and how fasting, nitric oxide, and gut health work together to optimize joint regeneration. You'll learn: • How cartilage cells (chondrocytes) rely on mitochondria for tissue repair • Why global cytokines like IL-6 and TNF-alpha drive joint degradation and brain fog • How cartilage begins to break down in your teens—and what to do about it now • The surprising clinical data on walking distance, inflammation markers, and recovery • Why most supplements and NSAIDs fail—and what actually rebuilds joints • How diet and leaky gut create 5-day inflammation spikes from a single fast-food meal • The mitochondrial link between joint pain, cardiovascular risk, and depression • Why perimenopausal women are at 10x higher risk for arthritis—and how to prevent it • How to track your biological joint age using imaging and systemic inflammation labs This is essential listening for anyone serious about biohacking, functional medicine, pain-free aging, and human performance. Whether you're lifting heavy, walking daily, or just trying to stay mobile into old age, this episode gives you the science and tools to reverse joint degeneration and extend your healthspan. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Joint cartilage regeneration, IL-6 inflammation suppression, TNF-alpha cytokine modulation, Chondrocyte mitochondrial repair, Catabolic to anabolic tissue shift, Osteoarthritis reversal, Rheumatoid arthritis inflammation, Mitochondria and collagen synthesis, Boswellia seratol extract, Celery seed COX inhibition, Matrix metalloproteinase (MMP) inhibition, Synovial fluid inflammation, Leaky gut and joint pain, Six-minute walk test improvement, Global cytokine markers, High sensitivity CRP reduction, ESR sedimentation rate, Uric acid crystal formation, Post-prandial glucose walking, Cartilage MRI biomarkers, Functional medicine joint support, Fasted repair stacking, Vasodilation and nitric oxide, Anti-inflammatory supplement stacking, NF-kB pathway reduction, Joint space biological age, Microvascular circulation and cartilage, Caloric load and cytokine spike, Perimenopause and arthritis risk, Joint tissue anabolic activation **Get an exclusive discount for podcast listeners at calroy.com/dave : https://calroy.com/product/cartigenix-hp/?lp=dave ** Thank you to our sponsors! -BodyGuardz | Visit https://www.bodyguardz.com/ and use code DAVE for 25% off. -BiOptimizers | Go to http://bioptimizers.com/dave and use code DAVE15 to get 15% off your order. -Quantum Upgrade | Go to https://quantumupgrade.io/Dave for a free trial. -Caldera + Lab | Go to https://calderalab.com/DAVE and use code DAVE at checkout for 20% off your first order. Resources: • Danger Coffee: https://dangercoffee.com/discount/dave15 • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Trailer 1:25 — Introduction 2:01 — Why Modern Medicine Fails at Joint Pain 3:07 — Painkillers That Accelerate Joint Damage 7:35 — Rheumatoid vs. Osteoarthritis Explained 8:54 — Cytokines That Destroy Cartilage 12:10 — Arthritis Begins in Your Teens 15:35 — 75% Pain Reduction in 7 Days 18:35 — The Science Behind Boswellia & Celery Seed 24:10 — Six-Minute Walk Test Results 25:45 — The $200/Month Painkiller Trap 28:53 — Proof Cartilage Can Regrow 31:01 — Mitochondria and Joint Repair 32:29 — Inflammation Links to Heart Disease 35:52 — Why Glucosamine Doesn't Work 37:07 — Silent Arthritis in 90% of Adults 40:44 — Why Women Face Higher Joint Risk After 40 45:52 — Food as the #1 Inflammation Trigger 47:23 — Fasting & Cartogenics Stack for Repair 50:27 — Movement Snacks and Efficient Training 55:54 — Why Joints Heal Slower Than Muscles 57:48 — Dave's Stack and Final Takeaways See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Not Your Mother's Menopause,  Dr. Fiona Lovely is joined by Dr. Siobhan Matthews, a neuroscientist and Chief Scientific Officer at MitoQ, for a profound discussion on the pivotal role of mitochondria in brain health and aging. Dr. Matthews, whose career was inspired by her grandmother's experience with Alzheimer's, shares her extensive research journey on mitochondrial science, anti-aging the brain and nutritional neuroscience. The conversation illuminates the critical connection between mitochondrial health and the cognitive changes many women experience during perimenopause and menopause. Dr. Matthews explains how the decline in estrogen can directly impact mitochondrial function in the brain, potentially leading to symptoms like brain fog and fatigue. She provides insightful information on how supporting cellular energy production and protecting against oxidative stress can be a powerful strategy for maintaining cognitive vitality. The discussion also explores the broader implications of mitochondrial health for heart function, immune resilience, and overall longevity, offering a fresh perspective on proactive wellness for women navigating midlife and beyond. Find out more about MitoQ at mitoq.com - there is lots to learn!  (code: LOVELY for a discount!) Thank you to our sponsors for this episode:

In this episode of Curing with Sound, we explore a groundbreaking approach to one of medicine's toughest cancers, glioblastoma (GBM), with Michael Canney, PhD, Chief Scientific Officer at Carthera. GBM is the most aggressive form of brain cancer, notoriously hard to treat because the blood-brain barrier (BBB) blocks many life-saving drugs from reaching tumor cells. With survival rates of just one to two years, new approaches are urgently needed. Dr. Canney shares how Carthera's SonoCloud-9, an implantable, therapeutic ultrasound device, temporarily opens the BBB and enhances the delivery of circulating drugs to the brain. He also discusses the SONOBIRD clinical trial, comparing the use of Carthera's SonoCloud-9 device combined with chemotherapy to standard-of-care therapies in patients with recurrent GBM. Discussion highlights: Phase III SONOBIRD Trial: The largest clinical trial in Carthera's history, enrolling 560 patients across the United States and Europe. The trial's goal is to demonstrate a survival advantage for patients with recurrent GBM when BBB opening is combined with the delivery of carboplatin chemotherapy, as compared with standard of care. Revolutionizing Drug Delivery: How SonoCloud-9 opens the BBB to increase carboplatin concentrations five- to seven-fold, potentially unlocking the full potential of existing cancer drugs that previously couldn't reach brain tumors. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

Solutions to manage PMS Research is expanding in the field of premenstrual syndrome (PMS) and women are finding monthly relief with everyday nutritional interventions. In this Live Foreverish episode, Dr. Mike and Dr. Crystal sit down with Dr. Somashekara to discuss how PMS differs from other menstrual-related conditions, underlying causes, and nutritional extracts that can help. #LELEARN #EDULFsocial Guest Bio Somashekara Nirvanashetty, PhD, Co-Founder & Chief Scientific Officer, Olene Life Sciences Private Limited, is an accomplished biochemist with over 20 years of experience in pharmaceutical, nutraceutical, and agri-food innovation. He holds a PhD from Swinburne University of Technology, Australia, in collaboration with IIT-Madras. Dr. Somu has filed more than 45 patents, authored 10 peer-reviewed publications, and contributed to two book chapters.

Tyler O'Malley is the Vice President of Clinical Affairs, Bioinformatics, and Market Access at Exagen, Inc. Tyler shares his journey in the MedTech industry and discusses Exagen's innovative approaches to autoimmune testing solutions, including cutting-edge diagnostics for lupus and other diseases. With over a decade of experience, Tyler provides insights into the challenges and breakthroughs in the field, highlighting the significance of early diagnosis and personalized treatment, while also discussing the challenges and opportunities in effective leadership during different stages of company growth.   Guest links: https://exagen.com/ Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 066 - Tyler O'Malley [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and I am so excited to introduce you to my guest today, Tyler O'Malley. Tyler serves as Associate VP of Clinical Affairs and Market Access at Exagen, Inc., a leader in autoimmune testing solutions. In his role, he oversees clinical trials, bioinformatics, and medical policy development for Exagen's current diagnostic portfolio and pipeline of proprietary solutions. With more than a decade of experience, O'Malley has contributed to more than a dozen clinical trials focusing on clinical validity and utility evidence for autoimmune diagnostics. His expertise is widely recognized with numerous publications in esteemed peer reviewed journals, and notably, he's the first author of one of the largest clinical utility studies in lupus diagnostics. O'Malley graduated from Georgia Gwinnett College with a Bachelor of Science in biology, concentrating in biochemistry. His 11 year career in research and development and medical affairs encompass medical science, education, assay development, and clinical research coordination. Well, welcome to the show, Tyler. I'm so excited to have you here today. [00:02:01] Tyler O'Malley: Thanks, glad to be here. [00:02:02] Lindsey Dinneen: Yeah, absolutely. Well, I would love just starting off by telling us a little bit about yourself, your background, and what led you to MedTech. [00:02:11] Tyler O'Malley: Sure. So, I'm the Vice President of Clinical Affairs, Bioinformatics, and Market Access at Exagen. We're a specialty diagnostics company focused on autoimmune rheumatic diseases. So we develop proprietary testing technology for conditions like lupus, rheumatoid arthritis, Sjogren's disease, as well as many others. And yeah, our focus is trying to find solutions for patients who are dealing with what are many times challenging chronic diseases that can present themselves in very mysterious ways oftentimes. And so, these are challenges that patients have that have, for the most part, gone unsolved for many decades, and so there's a lot of opportunity out there. In terms of, myself, my background, I've been with Exagen for the past 11 and a half years. So I've been doing this for a while now, and I've worked in a couple of different areas within the organization, doing work within the lab assay development, as well as outside the lab doing clinical research, statistical analysis, which led to the bioinformatics role. And then as well as doing some work trying to align our clinical evidence with medical policy for our tests which is the market access role. So, a little bit of everything, but there are some through lines that I assure you do make some sense if you really think about it. [00:03:33] Lindsey Dinneen: Excellent. Excellent. Well, thank you for sharing a little bit about that. There's so much to dive into, but going back a little bit in your story, when you were thinking about careers-- you're a eager high school student ready to embrace college, and you're ready for the next step --is this something that you could have imagined yourself doing or has this always been a passion of yours? Or is this something you kind of found yourself in? [00:03:57] Tyler O'Malley: Not at all. So, no I, so I will say I've always been interested in autoimmunity. So that's always been something that has always piqued my interest, whether I was in high school or college. And so I guess in that sense, it's not a surprise. But the laboratory diagnostics component of it was not something that was on my radar when I was in high school or college. And I guess the journey to Exagen was, after graduating from high school, went and got a bachelor's degree in biology with a biochemistry focus. So, that's sort of my background there. And while I was getting the degree and focusing on biochemistry, I had the opportunity through a resource scholarship at Georgia Tech to work in a graduate lab, which was a really interesting experience where, you know, for a little over a year I had the opportunity to work alongside PhD candidates, postdocs, on a research project that was partially funded and get the experience and understand what it's like to work towards a PhD and what it would look like to kind of go down that path of graduate level research. And I think it had the opposite effect that it was intended to have in that it kind of showed me I didn't want to do that. So, I think in a lot of ways I was happy I had that experience 'cause it showed me before I went down that path that it was something I didn't wanna do. Nothing against it, I guess I wanted to do something that maybe had more of a translational impact, a little bit closer to the patient. And so, finished my degree, and at the time I was living in Georgia, so I finished my degree in Georgia, left and moved out to California, and ended up at Exagen by pure chance through a recruiter. And that was back in 2014, and basically just joined Exagen at the time when it was a smaller company, and grew with the company, and was fortunate enough to have the ability to learn a lot of different functions within the company as it grew, and there were a lot of different things that needed to be done a as the company was growing. And so it, it's been kind of a, an interesting ride since then. [00:06:08] Lindsey Dinneen: Yeah, absolutely. And of course all of those different experiences, I'm sure, have woven their way in, like you said. Sometimes you have to kind of look for that line, but there is one that's, apparent when you look back. So, can you talk a little bit more about the company, what it does, especially in regards to its testing technology, and I'd love to hear about some of the innovation that's just coming out of this incredible organization you're a part of. [00:06:35] Tyler O'Malley: Sure. So our our testing, again, primarily focuses on addressing unmet needs in patients who have autoimmune connective tissue diseases. And specifically we have some proprietary technology around biomarkers that help diagnose systemic lupus. And lupus is kind of the prototypical autoimmune disease in that it can manifest in just about any different way. It can show up in your skin, your heart, your lungs, your kidneys, just about any way you can imagine, and sometimes in multiple different ways. And so in that way, it can be challenging to diagnose 'cause it can look like so many different things. And much of the testing that is used for lupus or has been used traditionally is very antiquated. Antibody tests that were developed many decades ago that have been refined to some extent over the years, but for the most part are not overly sophisticated. So, what Exagen has done over the past 15 or so years is brought forward some technology, that was originally licensed from University of Pittsburgh, looking at measuring a form of the complement system, which is a part of our immune system. It's a very ancient form of our immune system. It's a collection of proteins that come together to help fight off pathogens and help clear debris to keep our our immune system healthy. And what we're able to do is measure essentially the buildup of a complement fragment that builds up on your red blood cells and on your B lymphocytes. And what this does is it gives us a unique ability to detect lupus that's much more sensitive than the conventional means. And what that means, when I say sensitivity, is that it's able to pick up more lupus patients than the conventional testing. So, one way of thinking about this is like, if you have a hundred patients in a room that all have lupus, right? Because they've been assessed by a doctor, they've been clinically diagnosed, and you were to test them, and say your conventional test is 50% sensitive, meaning half of the room would test positive on this test and the other half would test negative. This test that we're talking about here, it would pick up two thirds of the room, right, as opposed to conventional testing, which would pick up fewer patients. So, that's the kind of technology that we're trying to develop here, which is trying to be more inclusive, pick up more patients sooner, give better insights to physicians to combine with their clinical assessments such that patients can get earlier treatments and hopefully stave off some of the more kind of disastrous outcomes of the disease that come with not getting treated soon enough and not getting treated appropriately for their symptoms. [00:09:31] Lindsey Dinneen: Yeah, of course. That's incredibly important and I'm so glad that the company is working to create those solutions, like you said, because previous methods while maybe somewhat useful, are more antiquated at this point. And so it's really important to have these new strides in innovation. So as you're dealing with all of this, I'm sure that there are stories that have come up about real people having impacted lives because of the technology that your company is bringing. Do you have any examples that you could share with us about that? [00:10:05] Tyler O'Malley: Sure. Yeah, there's been a number of individuals that we've had the fortune of meeting over the years. And they come and share the story with our team. We like to bring folks in with, for example, when we bring on new sales team members, we try to bring on a patient just to be able to share their story. So, recently we had an individual, who is connected to someone who works in our organization-- again, just pure chance-- who happened to have a very unique story. So first of all, lupus, for those who don't know, is a condition that primarily affects women. Lupus is a disease that affects women at a ratio of nine to one, nine to one female to male or so, in other words, around 90% of lupus patients are women. But that's not to say that it isn't an issue for that subset of of men that do develop lupus. And in fact, the disease tends to be more severe in that 10% of lupus patients that are men. So this individual who we've had the chance to meet and hear his story, really interesting because he's-- you would never know if you met this guy-- because he's a CrossFit guy. He is probably the healthiest guy you can imagine looking at him. But he went a harrowing journey to get to his diagnosis. And it all started with, relatively -- well, I don't wanna downplay it-- but let's call it "less severe symptoms" like alopecia and rashes, things like this that sort of make you think, "Well, gee, that's strange," or "I wonder what that is all about." And then leading up to much, much more severe symptoms like severe edema and pericarditis that was ultimately life threatening. And ultimately, he was able to get the right testing and get to the right doctors, but it was not a short journey from the time that these symptoms initially presented themselves to the time where he was able to get to the test and to get to the right diagnosis and onto the right treatment. The good news is, he's in a much better place now after finding out what's causing his symptoms and getting to a treatment management plan that works for him and he's even back to getting to an exercise routine that works for him. It's maybe not exactly the same as what it was before, but I mean, that's the thing. Now, you can lead a relatively normal life with lupus. It wasn't that long ago, call it several decades ago, where the mortality rate for lupus was as high as 50% in the first year after diagnosis. Treatment advances have greatly improved that and have changed the lives of people who live with Lupus now, but it used to be a very severe diagnosis. It still is, but it's very manageable now. [00:12:54] Lindsey Dinneen: Wow. Yeah. And so catching it and having that answer to, like you said, really difficult health journey where you're just not sure what's going on. And I really appreciate you talking a little bit about how Lupus looks different and manifests itself differently in different circumstances so it can be difficult to initially diagnose. So I love the fact that the company is focusing on things like that, when caught early can maybe make a huge difference in somebody's life like the gentleman you mentioned. Thank you for sharing about that. So now your own career has been really interesting in that you have gotten to do a lot of different things within the company and learn so much. Now as you've continued to grow with the company, you've, I'm sure, developed a lot of different leadership skills along the way, and I'm curious what it's been like in that sense of your journey to embrace leadership and how do you go about it? What have you found works really well, and maybe what advice would you have for somebody who's a little bit earlier in their career? [00:13:58] Tyler O'Malley: Yeah. Really interesting question. And I, I guess, my experience was, I came into an organization that was, I think at the time, maybe in the entire company was maybe 60, 70 people. So, as you can imagine, it was a very flat organization. I reported directly to the Chief Scientific Officer when I first joined the organization as a relatively low level R&D employee. So that afforded me, I think, a unique opportunity because I was often involved with project planning and discussions that I don't know that you get that opportunity in different types of corporate settings. And I think what has proven very useful in terms of my development, and as I look back and reflect on kind of what's led me here is, I can just recall, so, so many times, especially early on in, in a startup-- which can sometimes be chaotic and there's a lot of moving parts and things are moving fast-- there would be times where I would be in meetings where I wasn't necessarily expected to do very much, I think, or contribute much. And I would just sort of observe, right? And I think there's so much you can learn through not just listening to the conversation, but the body language of the people around the table. The way that people present, the way that people take criticism, the way that they respond. It was almost like a, it was a lesson every day just watching that. And I think where I thrived and maybe added value at times was realizing when people were talking past one another and just, at times, trying to find a way to come into that and say, "Well, right, but did you consider maybe what this person was trying to communicate here?" And, you can't always resolve those sorts of situations, but sometimes you can. And that's really valuable when you can help two individuals get past an impasse like that. So, and I think it helps you build credibility doing that too, being a bridge builder in that sense. And, and I think, that was something I don't know-- whether intuitively or purely by accident, I don't know-- I figured out over time was that, maybe as a young person in your career, sometimes it can be easy to get caught up on sort of the X's and O's of your job, whatever it is that you're doing-- if you're a computer programmer, you're doing bioinformatics or whatever the case may be-- you can get really caught up in the technical skills that you're trying to hone and develop. But there's so many soft skills that you have to build as well at the same time. And there's the relationships that you build, as well, that you don't know when you're gonna need them or when they'll pay off. But things change at organizations and you're glad when you have those relationships when it comes time to need them. [00:16:51] Lindsey Dinneen: Yeah. Absolutely. Yeah. I love your discussion on the idea of being a bridge builder, because I've been thinking a lot about that recently where there's so much unintentional missed communication, just literally just passing by where, one person is saying something, the other person's saying something, and as an outsider, you're able to have a little bit of a distance to go, "Oh, you're kind of saying the same thing, but I'm not sure that you guys realize that, and here's how." Yeah, that translating is a really important skillset and a fun one when you can nail it down. So as you look towards the future of your own career and the company's trajectory, what are some things that you're looking forward to? [00:17:35] Tyler O'Malley: Well, we obviously have a number of exciting pipeline initiatives that bring a lot of energy to me as I think about what we're trying to do going forward. I'm excited about where the company is headed in terms of its trajectory. I've described my time at the company as, even though I've been at the same company for 11 and a half years or so, I really feel like I've worked for three different companies in that time, in that, there was a period of time that was a startup up until the point the company went public. And then there was this time from when the company was public, where we raised a lot of money, there were a lot of expectations and didn't exactly kind of work out exactly as we had hoped. And then there was a leadership change. And now we're sort of in this third phase now where the arrow's pointing up and we have realigned our strategy here and we found a way to be sustainable and to be able to continue to build on something where hopefully we can continue to find interesting technology that's out there. We have an ongoing partnership with, as an example, Johns Hopkins University to try to develop a test to help address lupus nephritis. So this is a particular form of organ manifestation of lupus. It's one of the more common manifestations of lupus, and one of the more devastating forms of lupus, in that almost 50% of lupus patients will have kidney involvement at some point in their disease. And as much as 10 to 20% of patients who do have lupus nephritis will go on to unfortunately develop end stage kidney disease and require dialysis or kidney transplant. So it's obviously life altering and can be, very impactful to individuals. So, to be able to work on something like that and be able to potentially alter the trajectory of someone's life in that way is pretty cool to think about. And, not everyone gets to do that. I mean, it's not that other jobs aren't meaningful, it's just not everyone gets the opportunity to do that kind of thing. And if you can also find joy in what you're doing in your job. I think that's also great too. I mean, it's really cliche, the things people say, and so I won't do it. The whole, like, " If you like what you do, you never work." Believe me, it's work. I do feel like I'm working sometimes, for sure, but I can't complain. I do, for the most part, have fun with what I'm doing. I'm fortunate enough, I have a great team of people, well-- three teams of people-- that I really enjoy working with, and being able to work with people and see them grow and develop and be a part of that is also super rewarding as well too. So, yeah, I'm just, I'm having a lot of fun. [00:20:26] Lindsey Dinneen: Yeah. Excellent. Wonderful. Well, gosh, I'm gonna pivot the conversation just for fun a little bit. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. Now, this could be within your industry, but it doesn't have to be. What would you choose to teach? [00:20:45] Tyler O'Malley: I think that-- maybe this is kind of fun, probably not-- but I think that ,I don't know why, and it's funny because it's-- I don't even know if this qualifies because I don't even know how I would teach it-- but I think I'm fairly good at guesstimating numbers and it's really useful in that it helps in a lot of different situations to be able to shortcut math. And to be clear, it's not that I'm doing long division in my head or anything like that, but it's, if you can kind of shortcut and get the approximate number, it can be really useful. And it's a nice kind of party trick too kind of thing. Again, I don't know how I would teach it 'cause it's sort of like it's up here, and I don't know how I would externalize that, but yeah, that's something I feel like would be kind of cool to figure out how I could teach that. [00:21:35] Lindsey Dinneen: Absolutely. Yeah. It's a superpower. So it would be very cool to try to then-- you've got this innate ability-- so then to try to break it down into how does somebody else develop the skill sets that you just sort of possess, and go from there. That would be really entertaining. I love it. Great answer. Okay. And then the next question is, how do you wish to be remembered after you leave this world? [00:21:59] Tyler O'Malley: Yeah. Well, that's a deep question. I think that the most meaningful impact that you can have is the impression you leave on the people that you interacted with, right? And I think, for me, I would just hope that the people that I've had the chance to spend time with-- obviously family, friends, people I worked with, people who worked on my teams-- I would just hope that as they would reflect on the time that we had together, that it would be a memory that was time well spent and that hopefully there are some good shared experiences that we had and that hopefully I left something that was meaningful. But as it relates to the work that we're doing, I hope that the impact that we're having-- some of it has a longer reach than even what we can see today, 'cause I think, truly being selfless is trying to build things that you'll never realize the benefit of: planting trees that you'll never sit under yourself. It's for someone else down the line in the future. [00:23:14] Lindsey Dinneen: Yeah. Yeah. I love thinking about it in those terms too: being willing to do your bits of good and let them go out into the world and not necessarily know the ripple effects and still use that as a worthwhile use of your time. I love that. And then final question, what is one thing that makes you smile every time you see or think about it? [00:23:39] Tyler O'Malley: Yeah, I think the easy answer is probably my kids. So I have two kids, and that's kind of the reprieve from the work life and kind of focusing on all this important stuff that we're trying to do here at work, but being able to kind of break away from that and focus on building them up and watching them grow and develop and become their own person is really cool. It's obviously a unique experience and it's a nice thing to be able to think about when you need something to kind of bring you back up. [00:24:12] Lindsey Dinneen: Yeah, absolutely. Just a different way of looking at the world from such a fun perspective. I love that. [00:24:19] Tyler O'Malley: Yeah. [00:24:20] Lindsey Dinneen: Yeah. Well, Tyler, this has been such a great conversation. I so appreciate your time today telling us a little bit about your story, the company, and all the incredible work that you guys are doing to change lives for a better world. And we are so honored to be making a donation on your behalf as a thank you for your time today to Save the Children, which works to end the cycle of poverty by ensuring communities have the resources to provide children with a healthy, educational, and safe environment. So thank you so much for choosing that charity to support, and thank you so much for being here and thank you for doing what you do. [00:24:59] Tyler O'Malley: Thank you. It's it's been a pleasure. [00:25:01] Lindsey Dinneen: Excellent, and thank you also to our listeners for tuning in, and if you're feeling as inspired as I am, I'd love it if you'd share this episode with a colleague or two and we'll catch you next time. [00:25:14] Dan Purvis:  The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world. 

Episode Description:  Not sure if you should receive a vaccine given your psoriasis or psoriatic arthritis medication?  Dermatologist Dr. Jason Hawkes explores this question along with vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis. Listen as hosts Jeff Brown and LB Herbert discuss key questions about vaccine use and psoriatic disease with dermatologist and NPF Medical Board member Dr. Jason Hawkes who is co-owner, Chief Scientific Officer, and investigator with the Oregon Medical Research Center. Hear what the difference is between live and non-live vaccines, how type of vaccine and immunosuppressive medications impact the timing of vaccines in relation to treatment half-lives. Get your questions answered. The intent of this episode is to offer answers to questions about vaccine use for people with psoriasis and psoriatic arthritis who take immunosuppressive treatments.   Timestamps: (0:23) Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. Jason Hawkes. (1:15) In general, what is a vaccine and how it works in the body. (2:08) Will vaccines provide the same level of protection in people with psoriatic disease who are         on treatments that influence the immune system. (4:53) The difference between live and non-live vaccines.   (8:57) Summary of NPF Vaccine Recommendations in relation to live and non-live vaccines and             specific medications for psoriatic disease, including a definition of medication half-lives. (13:38) Vaccines that may be recommended prior to starting a systemic medication or biologic. (18:27) The mRNA vaccine – how it works in comparison to other vaccines. (22:31) How long immunity lasts from childhood vaccines. (25:24) The vaccine guidelines apply to both psoriasis and psoriatic arthritis with some nuances.      (28:38) Which healthcare provider to turn to for advice about vaccines and why. (31:54) Questions to ask your health care provider about vaccines. (33:26) How clinical trials and registries are evolving to assess the effect of vaccines with specific             medications and the need for greater understanding. (36:44) Develop a good relationship with your health care provider and don't be afraid to ask                 questions about your psoriatic disease, vaccines, or specific medications. Key Takeaways: ·       Vaccines work to help protect the body or stimulate protection against common infections or pathogens. There are different types that can be classified as either live or non-live vaccines.   ·       Evidence-based vaccine recommendations are available for people with psoriasis and psoriatic arthritis to help guide timing of when to receive live and non-live vaccines when taking immunosuppressive oral systemic medications and/or biologics.   ·       It's important to discuss which vaccines to consider, and how current psoriasis medication could impact the intended response and timing  with your health care team which includes a primary care physician, a dermatologist, and/or rheumatologist.    Guest Bio: Dermatologist Jason Hawkes, M.D., MS is Co-owner, Chief Scientific Officer and Investigator with Oregon Medical Research Center (OMRC) in Portland, Oregon. He is also a Clinical Assistant Professor of Dermatology at Oregon Health and Science University and the President and Sole Member of Hawkes Dermatology. Prior to joining the Oregon Medical Research Center, Dr. Hawkes held academic faculty appointments in the Departments of Dermatology at the University of Utah School of Medicine, Icahn School of Medicine at Mount Sinai, and University of California-Davis. Dr. Hawkes' principal clinical and research interests are the treatment of complex inflammatory skin diseases, such as psoriasis, hidradenitis suppurativa, chronic urticaria (hives), and eczema. He has a special interest in translational human research and the development of novel biologics and small molecules used for the treatment of inflammatory conditions. Dr. Hawkes is also a Councilor of the International Psoriasis Council (IPC) and serves on the Medical Board and Scientific Advisory Committee of the National Psoriasis Foundation (NPF) where he participates in the development of clinical consensus statements. Resources:         “Does Having Psoriatic Disease Impact Vaccine Choices?” Psound Bytes™ podcast with Dr. Sandy Chat (University of California) and Dr. Christoph Ellebrecht (Dept. of Dermatology, University of Pennsylvania).       Medical Board Clinical Statements                

This episode continues the discussion with Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, as they dive into the nuance, challenges and opportunities of autoinjectors and combination drug delivery systems.In this conversation they focus on supporting decentralized clinical studies and how connected technology can improve patient compliance, trust and cleaner data processing.This episode is presented in partnership with ⁠PII⁠.Host⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestsOliver Eden, Senior Business Unit Director, JabilTravis Webb, Chief Scientific Officer, PIIDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Matt Dowling is the Chief Scientific Officer and Director at Medcura Team. Matt completed his graduate work at the Fischell Department of Bioengineering at the University of Maryland (UMD), after completing his undergrad in Chemical Engineering from the University of Notre Dame. At UMD, he was awarded the Fischell Fellowship in Biomedical Engineering for his innovative ideas in drug delivery systems. Matt then co-created gel-e, a novel biomaterial platform, raising several initial grants to develop the technology and to launch Medcura as a corporate entity. Matt was the recipient of the Dean's Doctoral Research Award from the UMD Clark School of Engineering for his work on chitosan-based self-assembled soft materials for use in wound treatment. He has been the Principal Investigator on $10 million in non-dilutive grant awards to Medcura; these have been used to achieve 5 FDA clearances, 2 Breakthrough Device Designations, 28 issued patents, and 10+ peer-reviewed publications in high-impact journals. Matt's work has been featured on several US and international media outlets including the BBC TV program, Brave New World with Stephen Hawking. He's also the lead vocalist in the band, Swoll.Swollhttps://www.swollmusic.com/Light the NightLLS is on a mission to cure blood cancers and improve quality of life for the nearly 1.7 million people in the U.S. living with or in remission from blood cancer.Help Team Zavadowski reach our fundraising goal! Thank you for your generous donations:https://pages.lls.org/ltn/fdk/Montcomd25/rsmith--Get in touch: robinsmithshow@gmail.comCall the hotline: +1 (301) 458-0883Follow Robin on Insight Timer: https://insighttimer.com/robinsmithBecome a supporter on Patreon: https://www.patreon.com/therobinsmithshowGot a question? We'd love to hear from you!

In 2023, Molly Jacobson speaks with Dr. Michelle MacLeay, Chief Scientific Officer of the AKC Canine Health Foundation, about groundbreaking cancer research that dog owners are making possible. Topics include: • One Health Approach: How canine cancer research benefits both dogs and humans. • New Studies: Details on 13 new cancer studies funded this year, including those on hemangiosarcoma and genetic therapies. • Nutrition Challenges in Research: Why standardizing dog diets in studies is crucial. • Precision Medicine: Targeting cancer treatment based on the genetics of the dog and the tumor. • Funding and Collaboration: How breed clubs and donations are advancing canine health. • Learn how your support can contribute to saving lives and advancing science for both dogs and humans. Your Voice Matters! If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos: https://www.youtube.com/watch?v=WEvFhsC_TyY https://www.youtube.com/watch?v=_92w6TTXM5c Related Links: AKC Canine Health Foundation: https://www.akcchf.org/ Canine Health Foundation Tribute Page: https://www.akcchf.org/how-to-help/tribute/ AKC Canine Health Foundation Facebook page: https://www.facebook.com/akccaninehealthfoundation One Health Initiative: https://onehealthinitiative.com/ Ethos Veterinary Health Clinical Studies: https://www.ethosvet.com/our-services/clinical-studies/ American Veterinary Medical Association Animal Health Studies Database: https://ebusiness.avma.org/aahsd/study_search.aspx Google Scholar: https://scholar.google.com/ Chapters: 00:00 Introduction 00:15 - Meet Dr. Michelle MacLeay 00:45 - What Is One Health? 02:00 - Challenges in cross-species research 06:15 – Dogs as environmental sentinels 08:00 - Hemangiosarcoma and Dog Cancer 13:15 - Precision Medicine 15:45 - Nutrition and Cancer Studies 18:30 - Hemangiosarcoma study 22:00 - Finding clinical trials 26:00 - Donating to Research 30:00 - New Frontiers 37:15 - New Dog Tips 40:45 - Get Involved Get to know Dr. Jennifer MacLeay: https://www.dogcancer.com/people/jennifer-macleay-dvm-phd-mba/ For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Les cancers du cerveau représentent 2% de l'ensemble des cancers en France soit environ 6000 cas par an. Il s'agit d'une pathologie rare, pour laquelle il n'existe pas de guérison possible à ce jour, et qui peut toucher tous types de personnes, même très jeunes.Dans cet épisode, nous chercherons à mieux comprendre les tumeurs cérébrales leurs symptômes, les traitements existants, la prise en charge des patients ainsi que les avancées de la recherche, notamment avec l'émergence des thérapies ciblées qui offrent de grands espoirs.Ecoutez le témoignage de Maya, 22 ans, une patiente atteinte d'un cancer du cerveau. Et les éclairages de Claude Bertrand, -Président Exécutif Recherche & Développement, Chief Scientific Officer chez Servier et du Docteur Delphine Larrieu, neuro-oncologue, Oncopole Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole.Ce HORS-SERIE est proposé par Servier. La rédaction du Parisien n'a pas participé à sa réalisation.Crédits :Ecriture et interviews : Alice Milot Réalisation, musique et mix : Pierre ChaffanjonProduction : Majora Prod Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

What if the solution to chronic wound healing has been floating in our oceans for 600 million years?Jellyfish collagen isn't just different from the cow and pig-derived materials used in medicine today. It's actually better at healing human tissue.I sit down with Dr Andrew Mearns-Spragg, Founder and Chief Scientific Officer at Jellagen, who's proving this remarkable claim with hard data. His research shows jellyfish collagen outperforms traditional materials in vocal fold repair, triggers faster transitions from inflammation to healing, and creates longer-lasting tissue structure. The secret lies in what Andrew calls "collagen type zero," an evolutionarily ancient form that our bodies recognise differently, prompting superior healing responses without the prolonged inflammatory reactions seen with mammalian sources.Beyond the compelling science, Andrew reveals how he built the world's first ISO-certified medical device manufacturing plant for jellyfish collagen from scratch. We explore the practical realities of sustainable harvesting (achieving near-zero bycatch), navigating FDA regulations for an entirely novel biomaterial, and convincing investors to back marine biotechnology. This venture extends beyond the laboratory. By harvesting jellyfish blooms caused by overfishing, Jellagen addresses an ecological problem while creating advanced wound care solutions and providing alternative income for local fishing communities struggling with depleted fish stocks."The jellyfish collagen transition to healing was much quicker and longer lasting." - Dr Andrew Mearns-SpraggYou'll Hear AboutWhy jellyfish collagen outperforms mammalian collagen in tissue healingThe challenges of building ISO-certified jellyfish manufacturingHow ancient collagen triggers better immune responsesSustainable harvesting methods with near-zero bycatchTranslating marine biology research into medical devicesThe cost of chronic wound management in healthcareNavigating the FDA regulatory pathway for novel biomaterialsSupporting local fishing communities through jellyfish harvestingFrom angel investment to medical device commercializationPlatform opportunities beyond wound healing applicationsConnect with Dr Andrew Mearns-SpraggLinkedIn - https://www.linkedin.com/in/andrew-m-006bb41/ Website - https://jellagen.co.uk/ Connect with me:LinkedIn: https://www.linkedin.com/in/markdavison100/ If you need any lab equipment:Grant Instruments: https://www.grantinstruments.com/ Grant Instruments on LinkedIn: https://www.linkedin.com/company/grant-instruments-cambridge-ltd/ 

Around 70,000 users of Discord globally could have had sensitive data stolen by hackers.The platform says criminals targeted a third-party service called 5CA, hired for age verification appeals.Data stolen includes official ID photographs, and potentially personal information such as partial credit card numbers and messages.A new tool is being developed by MI:RNA to help diagnose osteoarthritis in dogs earlier.Qualified vet and Chief Scientific Officer, Robert Coultous, joins us to tell us more.Acclaimed violinist Esther Abrami on London's Southbank Centre and TikTok's new accelerator programme for classical content creators.Also in this episode: -‘Viewing own face through baby filter could help unlock memories'-Scientists transplant a pig liver into a human-20,000 people to help drive mental health research-Incense bowl and helmet handle among finds at National Trust estate dig Hosted on Acast. See acast.com/privacy for more information.

Josh Lizer is the Chief Scientific Officer at MG Biologics. Josh takes us through everything about snake bites. From A-Z you will go in the field more confident than ever before. If this happens to your dog. National Snakebite Support www.nationalsnakebitesupport.org National Snakebite Support Facebook group (be sure to answer ALL the questions to join or your request will not be approved) https://www.facebook.com/groups/987850051297436/ Antivenom locator: www.veterinarysnakebite911.com Email Josh @ josh.lizer@mgbiologics.com or techsupport@mgbiologics.com               email me : josh.lizer@mgbiologics.com or techsupport@mgbiologics.com    

"I've always been a teacher at heart."Co-founder, co-owner, and Chief Scientific Officer of both Ferm Solutions and Wilderness Trail and an adjunct professor at James B. Beam Institute in the College of Agriculture at the University of Kentucky Dr. Pat Heist is our guest on the show today and we are digging down on distilling, leadership, and a whole lot more.  Dr. Hesit and Jay are discussing the journey that Dr. Heist engaged in that led to his study of plant pathology and a doctorate from the University of Kentucky, teaching medical microbiology, to eventually starting a distillery consultation company and a distillery of his own.  As if that wasn't enough for this episode, these two gentleman are also getting into the importance of being genuine particularly in a sales or entrepreneurial endeavor, being able to recognize opportunity and having the fortitude to seize on it when it is presented, and why it is never a bad idea to stop and think things through before making big decisions.  This is a truly wonderful conversation and Dr. Heist's incredible journey makes for one hell of an interesting story.  We hope you enjoy this episode of The Culture Matters Podcast.

Clinical trials can present many challenges for patients–particularly injections.Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, discuss nuance, challenges and opportunities of autoinjectors and combination drug delivery systems.Additionally, they advocate that drug delivery systems enter the conversation earlier in clinical development stages given interdependencies. This episode is presented in partnership with PII.Host⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestsOliver Eden, Senior Business Unit Director, JabilTravis Webb, Chief Scientific Officer, PIIDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

In this special bonus episode of Nobel Prize Conversations, we shine a light on the many ways achievements in science are celebrated — from quiet late-night breakthroughs in the lab to the glittering applause of the Nobel Prize award ceremony. Host Karin Svensson speaks with Adam Smith, Chief Scientific Officer at Nobel Prize Outreach, about why recognition matters, how laureates share their joy with families, colleagues, and entire communities, and how the Nobel Prize captures the world's attention to honour the spirit of discovery. Along the way, we hear stories of invention, laughter, music, and even unexpected traditions from Nobel Prize laureates Peter Agre, Jim Allison, Frances Arnold, John Jumper, Katalin Karikó, Benjamin List, David McMillan, John O'Keefe, Paul Romer, George Smith and Donna Strickland. Through their lives and work, failures and successes – get to know the individuals who have been awarded the Nobel Prize on the Nobel Prize Conversations podcast. Find it on Acast, or wherever you listen to pods. https://linktr.ee/NobelPrizeConversations Hosted on Acast. See acast.com/privacy for more information.

Lyme disease is a bacterial infection passed on to humans by infected ticks. Symptoms can range from fatigue, joint pain and a circular shaped rash to facial paralysis and heart arrythmia. According to a British Medical Journal (BMJ) global health review, Lyme disease has likely infected about one in 10 people across the globe. Recently, pop star Justin Timberlake went public about contracting the condition. If treated quickly, most people will recover but there are still issues around diagnosing and treating Lyme disease. And globally, cases are on the rise. In this edition of The Inquiry, Charmaine Cozier explores what's behind the increase and hears about new tests and vaccines currently being developed. Contributors: Dr Sally Mavin, clinical scientist and Director of the Scottish Lyme Disease and Tick-Borne Infections Reference Laboratory, Raigmore Hospital, Inverness, Scotland Dr Armin Alaedini, Chief Scientific Officer, Global Lyme Alliance Dr Gábor Földvári, research group leader, Centre for Ecological Research, Institute of Evolution, Budapest, Hungary Dr Alessandra Luchini, Professor, School of Systems Biology, George Mason University, USA. Presenter: Charmaine Cozier Producers: Jill Collins and Emma Forde Researcher: Maeve Schaffer Technical producer: Richard Hannaford Production Coordinator: Tammy Snow Editor: Tara McDermott

If you've been following From Lab to Launch for a while, you may remember a previous conversation with Sapient's Chief Scientific Officer, Dr. Mo Jain, a couple years back. We're thrilled to build on that conversation with Dr. Jonathan Usuka, the CEO of Sapient. Sapient is one of the largest capacity biomarker discovery labs in the world, and their mission is to accelerate drug development and improve patient outcomes through biomarker-guided therapeutics. By combining high-resolution biomolecular data with advanced computational approaches, Sapient is helping sponsors and researchers unlock new therapeutic targets and navigate complex biology at unprecedented speed and scale.With more than 25 years of experience at the intersection of business, science, and technology, Jonathan has led innovation strategies across drug development, diagnostics, and AI-driven discovery. From streamlining therapeutic pipelines to pushing the boundaries of integrated diagnostics, his work is helping reshape how biopharma organizations bring life-changing therapies to patients. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode of Grow Everything, hosts Karl Schmieder and Erum Azeez sit down with Dr. Alessandra Zonari, co-founder and Chief Scientific Officer at OneSkin. Alessandra shares her personal journey from Brazil to biotech, driven by a mission to transform how we think about aging. She explains the science of cellular senescence, the discovery of the groundbreaking OS-1 peptide, and why skin is more than a beauty surface—it's a window into systemic health and longevity. Listeners will hear candid insights into the challenges of translating biotech discoveries into consumer products, the importance of radical transparency in science communication, and where peptides and personalized skincare fit into the future of the longevity movement. This is a must-listen for anyone passionate about synthetic biology, sustainable innovation, and the science of healthy agingGrow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at www.messaginglab.com/groweverythingChapters:(00:00:00) Welcome to Grow Everything Podcast(00:00:18) London's Bio Fab Fair Recap(00:02:34) Biotech's Bottom Line Impact(00:05:49) Pharma's Path to Consumer Products(00:08:00) The Accidental Discovery of Splenda(00:09:26) Meet Dr. Alessandra Zonari(00:10:54) A Scientist's Personal Mission(00:13:15) "Zombie Cells" and Skin Aging(00:16:30) Longevity Science vs. Marketing(00:18:28) The Hunt for the OS-01 Peptide(00:21:39) The Five-Year Path to Market(00:22:49) Science-First Communication(00:28:21) The Challenge of Going to Market(00:31:16) Communicating to Beauty vs. Biotech(00:33:45) The Future: Personalized Peptides(00:36:24) Why Science Storytelling Fails(00:38:42) Advice for Scientist-Founders(00:40:00) Peptide vs. SPF(00:40:42) Busting the Biggest Aging Myth(00:41:11) The Future of Personalized Aging(00:43:33) Why Aging is "Excited"(00:44:15) Actress or Astronaut(00:46:17) Peptides as "Cell Messages"Episode Links:Julie wolf episodeOneSkinTopics Covered: skincare, cellular senescence, peptides, OneSkin, skin health, anti aging  Have a question or comment? Message us here:Text or Call (804) 505-5553

We love to hear from our listeners. Send us a message.On episode 112 of Cell & Gene: The Podcast, Michael Quigley, Ph.D., Chief Scientific Officer and Global Head of Research at Sanofi talks to Host Erin Harris about the establishment of Sanofi's dedicated Genomic Medicine Unit (GMU). Dr. Quigley emphasizes in vivo delivery and process optimization to improve patient experience, scalability, and global access. They discuss the importance of partnerships with academia, industry, and regulators, and Dr. Quigley discusses how advances in AI are accelerating research efficiency, molecule optimization, and experimental design across Sanofi's portfolio. He also points to the breakthroughs likely to revolutionize immunology and gene therapy, such as solutions to pre-existing immunity barriers, improved tissue-specific delivery, regulated and reversible gene therapies, and more precise gene editing. Cell & Gene: The Podcast and Cell & Gene are part of the Life Science Connect family of resources.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Never miss another webinar! Signup here: https://imahealth.org/weekly-webinars/ Learn more: https://imahealth.org/stage-4-to-remissionHe was told he had less than a year to live. Now, he's here to tell the story of his incredible recovery. In this inspiring webinar, stage IV cancer survivor Dale Atkinson joins Dr. Amanda King, IMA Senior Fellow Dr. Kristina Carman, and host Dr. Paul Marik, IMA Co-Founder and Chief Scientific Officer, to share how integrative oncology helped him rewrite the ending.From devastating diagnosis to hope, Dale walks us through the treatments that made a difference, the turning points that kept him going, and the partnership with Dr. King that brought hope where there once was none. This isn't just a survivor story—it's a blueprint for blending conventional care with personalized, holistic approaches to chronic disease.• Donate: https://imahealth.org/donate/• Follow: https://imahealth.org/contact/• Webinar: https://imahealth.org/category/weekly-webinars/• Treatment: https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/About IMA (Formerly FLCCC Alliance)The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system.For more information about the Independent Medical Alliance, visit www.IMAhealth.org

Matias interviews Rob Malenka, Chief Scientific Officer of Bayshore, the family office of Google co-founder Sergey Brin.  Bayshore has played a major role in advancing treatments for Parkinson's, bipolar, and autism. In this episode, we discuss:Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneousThe bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma's avoidance of neuropsychiatryHow breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropyHow success depends on mission-driven, ethical people who align science, capital, and patient impact.The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.Credits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky Produced by Caitlin Ner & Nico V. Rey Find us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Dr. Ari Vojdani, Chief Scientific Officer at Cyrex Labs, describes the two primary components of the immune system--humoral and cell-mediated immunity and how the Cyrex diagnostics are designed to measure both. The Cyrex food immune reactivity testing measures antibodies against raw, cooked, modified, and processed food proteins as the structure of these proteins can change and affect immune responses. Cyrex is also developing tests to measure antibodies against various gut bacteria, fungi, and toxins, and how these relate to autoimmune conditions. Ari explains, "Cyrex performs lots of tests, but we can divide them based on the immune system. As you know, the immune system has two major components, the humoral and cell-mediated immunity. The humoral components of the immune system deal with measurements of antibodies. So when we get exposed to certain antigens, proteins of pathogens, food, or toxic chemicals, when they bind to human tissue, our body reacts to them, and the end result of that is specific antibody production against that specific protein or antigen." "The second component of the immune system is cell-mediated immunity, which looks at different lymphocytes, their markers, such as whether it is a T-cell, B-cell, CD4, CD8, T helper 1, T helper 2, regulatory T cells, or natural killer cells. So that also could be abnormal in certain inflammatory and autoimmune disorders. That's why at Cyrex, the tests that they are performing are classified based on humoral and cell-mediated immunity."   "In 1986 and 1987, I developed the ELISA method for measuring antibodies against different food antigens. Then I did not have the knowledge about the importance of raw versus cooked or raw versus modified foods. I established the methodologies, and many others came to visit my laboratories. Years later, they started their own laboratories. So they continue using the same raw food for measuring antibodies in their own laboratories." #CyrexLabs #FunctionalImmunology #FunctionalMedicine #immuneHealth #FoodSensitivity #FoodAllergies cyrexlabs.com Download the transcript here

Dr. Ari Vojdani, Chief Scientific Officer at Cyrex Labs, describes the two primary components of the immune system--humoral and cell-mediated immunity and how the Cyrex diagnostics are designed to measure both. The Cyrex food immune reactivity testing measures antibodies against raw, cooked, modified, and processed food proteins as the structure of these proteins can change and affect immune responses. Cyrex is also developing tests to measure antibodies against various gut bacteria, fungi, and toxins, and how these relate to autoimmune conditions. Ari explains, "Cyrex performs lots of tests, but we can divide them based on the immune system. As you know, the immune system has two major components, the humoral and cell-mediated immunity. The humoral components of the immune system deal with measurements of antibodies. So when we get exposed to certain antigens, proteins of pathogens, food, or toxic chemicals, when they bind to human tissue, our body reacts to them, and the end result of that is specific antibody production against that specific protein or antigen." "The second component of the immune system is cell-mediated immunity, which looks at different lymphocytes, their markers, such as whether it is a T-cell, B-cell, CD4, CD8, T helper 1, T helper 2, regulatory T cells, or natural killer cells. So that also could be abnormal in certain inflammatory and autoimmune disorders. That's why at Cyrex, the tests that they are performing are classified based on humoral and cell-mediated immunity."   "In 1986 and 1987, I developed the ELISA method for measuring antibodies against different food antigens. Then I did not have the knowledge about the importance of raw versus cooked or raw versus modified foods. I established the methodologies, and many others came to visit my laboratories. Years later, they started their own laboratories. So they continue using the same raw food for measuring antibodies in their own laboratories." #CyrexLabs #FunctionalImmunology #FunctionalMedicine #immuneHealth #FoodSensitivity #FoodAllergies cyrexlabs.com Listen to the podcast here

Sean Campbell, M.D., and Augustine Saiz, M.D., from UC Davis join Assoc. Prof. Hannah Dailey, OrthoXel's Chief Scientific Officer, to discuss the challenges of tibial fracture healing and the role of controlled axial micromotion in patient outcomes. Drawing on both research and real-world cases, they examine mechanobiology, patient risk factors, nonunion concerns, and share their initial clinical experiences with the Apex Tibial Nailing System, where micromotion has shown clear benefits. Explore the full episode resources on our website → https://shorturl.at/0eJU6 Connect with us on LinkedIn → https://shorturl.at/Dul3G Disclaimer: The views and opinions expressed in this industry sponsored podcast are those of the presenters and sponsor and do not necessarily reflect the views of the OTA.  Inclusion of industry supported content on the OTA podcast platform should not be interpreted as an endorsement of any product, service, or company.

Florida Surgeon General Dr. Joseph Ladapo made a surprise announcement that MAHA has been waiting for: ALL vaccine mandates are ending in the state. “Is it appropriate for a government or any other entity to dictate to you what you should put in your body?” says Dr. Ladapo. “No, it's absolutely not appropriate. You have sovereignty over your body…” Ladapo assured CNN the vaccines will still be available to anyone who wants them – just not mandated. Donald Trump, however, does not fully agree with the change. The President, who recently dined with tech moguls including Bill Gates, said: “You have vaccines that work. They pure and simple work. They're not controversial at all. And I think those vaccines should be used; otherwise, some people are going to catch it and they are going to endanger other people.” Dr. Peter McCullough is a cardiologist, internist, and epidemiologist, serving as Chief Scientific Officer of The Wellness Company. He co-authored “Vaccines: Mythology, Ideology, and Reality” and “The Courage to Face COVID-19.” Follow at https://x.com/P_McCulloughMD Christina Bobb is a national security attorney, former OAN reporter, and author of “Defiant: Inside the Mar-a-Lago Raid and the Left's Ongoing Lawfare.” She served as Senior Counsel for the RNC's Election Integrity section. Follow at https://x.com/christina_bobb Rob Schneider is an actor, comedian, and star of Netflix's “Real Rob.” He authored “You Can Do It: Speak Your Mind America!” Follow at https://x.com/robschneider 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

Buckle up for a trip (pun intended) into the midlife brain. This week we sit down with neuroscientist Dr. Grace Blest-Hopley to connect the dots between cannabinoids, psychedelics, trauma, and the menopause transition. We cover CBD/THC for sleep, anxiety, pain, and inflammation; how the endocannabinoid system works, and how psychedelics like psilocybin act on serotonin pathways, reduce neuroinflammation, and promote neuroplasticity—potentially countering some brain changes seen with estrogen loss. We also dig into trauma (including why PTSD risk and expression differ by sex), the importance of set, setting, and skilled facilitation, who should not use psychedelics, the legal/clinical landscape, and much more. Curious about midlife brain health and whether these therapies are worth exploring? This one's for you.Dr. Grace Blest-Hopley is a neuroscientist with 12 years experience researching cannabis, cannabinoids, and psychedelics. Grace completed her PhD in Neuroscience at King's College London and currently serves as the Chief Scientific Officer at NWPharma Tech. She is the Research Director at Heroic Hearts Project, a charity that supports combat veterans with mental health challenges resulting from trauma and is also the founder of Hystelica, a community focused on understanding women's biology for safe and effective psychedelic use. In addition to her research and professional roles, she has served as an officer in the British Army Reserve. Dr. Blest-Hopley advocates for the therapeutic potential of these substances and strives to advance the field of psychedelic research. Her work contributes to promoting a better understanding of women's biology in relation to psychedelics. You can learn more about her and her work at hystelica.comSign up for our FREE Feisty 40+ newsletter: https://feistymedia.ac-page.com/feisty-40-sign-up-pageLearn More and Register for our Feisty 40+ Strong Retreat: https://www.womensperformance.com/strongretreat Learn More and Register for our 2026 Tucson Bike Camp: https://www.girlsgonegravel.com/camp Follow Us on Instagram:Feisty Menopause: @feistymenopause Hit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099 Support our Partners:Phosis: Use the code FEISTY15 for 15% off at https://www.phosis.com/ Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/Hettas: Use code FEISTY20 for 20% off at https://hettas.com/ Previnex: Get 15% off your first order with code HITPLAY at https://www.previnex.com/ Nutrisense: Go to nutrisense.io/hitplay and use code: HITPLAY to get 30% off This podcast uses the following third-party services for analysis: Spotify Ad Analytics - https://www.spotify.com/us/legal/ad-analytics-privacy-policy/Podcorn - https://podcorn.com/privacyPodscribe - https://podscribe.com/privacy

Dr. Jeff Firewalker Schmitt's exceptional career is defined by a confluence of science, innovation, and leadership. With over four decades of experience, he has cultivated a reputation as a trailblazer in the integration of technology and life sciences. His tenure at ilumivu/Cardiogram as Chief Data Scientist showcased his prowess in marrying technology with healthcare, where he played an instrumental role in developing new diagnostic tools for wearable devices. This includes the successful launch of MigraineIQ, an innovative application leveraging smartwatch technology for health monitoring. At Sanesco International Inc., Dr. Schmitt's expertise as Chief Scientific Officer was pivotal in advancing translational research within the realm of non-pharmaceutical interventions to address imbalances in the human stress response system (HPAT axis). His earlier academic role as a Professor and Research Scientist at Wake Forest Baptist Health provided him with a robust foundation in biochemistry, biophysics and pharmacology, fueled major scientific contributions in the arena of cellular communication (signal transduction) as well as protein structure and function. He is among the youngest people in America to publish a peer-reviewed publication (age 15). As a luminary in innovation, Dr. Schmitt was the founding scientific director of Wake Innovations at Wake Forest University Baptist Medical Center. There he fostered an environment that propelled faculty technology commercialization, further cementing his status as a key figure in the development of one of North America's largest urban research parks. His directorial roles at both Bent Creek Institute and The North Carolina Arboretum were marked by strategic planning and alliance-building, underscoring his ability to drive research agendas forward through collaborative efforts. Dr. Schmitt's executive board experiences extend to The Media Arts Project where he led a significant organizational restructuring. His time at Targacept, Inc., as Director of Molecular Design, was particularly notable for pioneering the use of Machine Learning and AI in life sciences—yielding 30 patents and co-designing three clinical trial drugs. His scholarly achievements are equally impressive, with over 100 publications and patents to his name. Dr. Schmitt has been instrumental in raising over $150 million in venture funding—a testament to his acumen as a business developer and strategic thinker. He is a one-time recipient of the most prestigious federal research grant awards, the NIST Advanced Technology Program grant that provided multimillion dollar funding for his research in quantum molecular dynamics. Educationally, Dr. Schmitt has earned prestigious degrees from the University of Bath and University of Oxford in Biophysics/Biochemistry, enriching his expertise with an international perspective that informs his multifaceted approach to science and business. With active engagement in professional communities like Machine Learning Community and Wake Forest Innovations, Dr. Schmitt continues to influence fields ranging from neuroscience to social entrepreneurship—a true embodiment of leadership that bridges the gap between theory and practice. As the visionary Founder and Director of Eagle Condor Council, Dr. Schmitt promotes education and advocacy rooted in Native Wisdom Traditions and Eco-Spirituality, demonstrating his commitment to harmonizing scientific endeavors with ecological and spiritual principles.Episode Highlights▶Jeff's unexpected journey to the Eagle Condor Council and how his path unfolded.▶  The sacred role of tobacco as a plant medicine and how its meaning has been misunderstood today.▶  The importance of Chakaruna—bridge people who connect different realms of wisdom and experience.▶  Why openness, humility, and receptivity are essential in this evolutionary time.▶  How storytelling can unite diverse perspectives and support community healing.▶  The ways AI can expand human consciousness when used responsibly and creatively.▶  The challenges of cultural appropriation and the importance of respecting indigenous traditions.▶  The need for healing in modern society as we face disconnection from nature and industrialization.▶  How the powers of manifestation are amplified in our current era, creating space for positive change.▶  A vision of hope for humanity rooted in collective understanding and learning from the past.Jeff Firewalker's Links & Resources▶ Website: eaglecondorcouncil.org▶ Website: golden-threads.com▶ Website:  wisdomkeepers.earth  Download Beth's free trainings here: Clarity to Clients: Start & Grow a Transformational Coaching, Healing, Spiritual, or Psychedelic Business: https://bethaweinstein.com/grow-your-spiritual-businessIntegrating Psychedelics & Sacred Medicines Into Business: https://bethaweinstein.com/psychedelics-in-business▶ Beth's Coaching & Guidance: https://bethaweinstein.com/coaching ▶ Beth's Offerings & Courses: https://bethaweinstein.com/services▶ Instagram: @bethaweinstein ▶ FB: / bethw.nyc + bethweinsteinbiz ▶ Join the free Psychedelics & Purpose Community: / psychedelicsandsacredmedicines

Looking for the key to unlocking your energy and potential in perimenopause and beyond?  In this episode, I'm joined by nutritionist and health expert Cathy Eason of Berkeley Life to talk about one of the most overlooked molecules for women's health: nitric oxide. We dive into how nitric oxide supports cellular and mitochondrial energy, helping women feel more like themselves again in midlife. Cathy connects the dots between nitric oxide and women's hormonal health, metabolic resilience, and even sexual vitality.  So many common midlife struggles may actually stem from low nitric oxide levels, so Cathy's here to educate you on what exactly you can do about it to feel better… and fast.  Soon you'll see how this surprising molecule can help unlock more energy, vibrancy, and confidence as you navigate perimenopause and menopause.  Tune in here!  Cathy Eason Cathy Eason is a Board-Certified Holistic Nutritionist and the Chief Scientific Officer for Berkeley Life, with over 20 years of experience specializing in digestive health, autoimmune conditions, neuroendocrine dysfunction, and metabolic imbalances. Cathy's passionate about helping women thrive using natural, science-backed strategies — including the clinical power of nutraceuticals like nitric oxide support. IN THIS EPISODE The important benefits of nitric oxide for women in midlife  How estrogen decline in perimenopause impacts nitric oxide  Recognizing signals of oxidative stress in your body Important lab markers to check with your physician in midlife  Tracking metrics and testing your nitric oxide levels from home  Supplementing nitric oxide for optimal energy  Key nitric oxide-rich foods and nutrients to add to your diet Encouraging the natural production of nitric oxide in your body  Recommendations for reclaiming your vitality in midlife  QUOTES“We now know [this molecule] plays a role in women's health, especially in terms of gut function, in terms of sleep, in terms of immune function, hormone balancing, mental and emotional function, heart health, cardiovascular, and sexual function, too.”  “I'm a nutritionist, so I'm always looking for people to get dietary nitrates in food form, but knowing the levels of oxidative stress that we all experience, I know the need to supplement is also very foundational and very supportive of cardiometabolic health and my energy.” RESOURCES MENTIONED Nitric Oxide Foundation Discount Code: THRIVE15 for 15% off your order!

This week, we went to the doctor. Oz speaks with Dr. Matthew Lungren, the Chief Scientific Officer for Microsoft Health & Life Sciences, who co-authored a study showing that AI diagnosed complex medical cases four times faster than human doctors. Dr. Lungren walked us through how multiple AI agents worked together to generate their diagnoses, what that means for the future of medicine—and how human doctors and AI could collaborate to build a more democratized healthcare system.See omnystudio.com/listener for privacy information.

Medicine stands at the threshold of a new era, where artificial intelligence and systems biology are working hand in hand to make care more personal, predictive, and precise than ever before. AI is already improving diagnostic accuracy, automating administrative tasks, and uncovering patterns in data—like retinal scans or genomics—that humans often miss. Rather than replacing doctors, AI enhances their ability to deliver more informed, precise, and efficient care. At the same time, individuals are gaining tools—from at-home diagnostics to wearable biosensors—that empower them to track and optimize their own health. This shift marks a move from reactive, disease-centered care to a proactive, data-driven model of scientific wellness. In this episode, I talk with Dr. Eric Topol, Dr. Nathan Price, Dr. Leroy Hood, Dr. Vijay Pande, and Daisy Wolf about how artificial intelligence, personalized data, and wearable technology are converging to radically transform medicine. Dr. Eric Topol is Executive Vice President of Scripps Research and founder/director of its Translational Institute, recognized as one of the top 10 most cited researchers in medicine with over 1,300 publications. A cardiologist and author of several bestselling books on the future of medicine, he leads major NIH grants in precision medicine and shares cutting-edge biomedical insights through his Ground Truths newsletter and podcast. Dr. Nathan Price is Chief Scientific Officer at Thorne HealthTech, author of The Age of Scientific Wellness, and a National Academy of Medicine Emerging Leader. He also serves on the Board on Life Sciences for the National Academies and is Affiliate Faculty in Bioengineering and Computer Science at the University of Washington. Dr. Leroy Hood is CEO and founder of Phenome Health, leading the Human Phenome Initiative to sequence and track the health of one million people over 10 years. A pioneer in systems biology and co-founder of 17 biotech companies, he is a recipient of the Lasker Prize, Kyoto Prize, and National Medal of Science. Dr. Vijay Pande is a General Partner at Andreessen Horowitz and founder of a16z Bio + Health, managing over $3 billion in life sciences and healthcare investments at the intersection of biology and AI. An Adjunct Professor at Stanford, he is known for his work in computational science, earning honors like the DeLano Prize and a Guinness World Record for Folding@Home. Daisy Wolf is an investing partner at Andreessen Horowitz, specializing in healthcare AI, consumer health, and healthcare-fintech innovation. She previously worked at Meta and in various startups, holds a JD from Yale Law, an MBA from Stanford, and a BA from Yale, and is based in New York City. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: Can AI Fix Our Health and Our Healthcare System? The Next Revolution In Medicine: Scientific Wellness, AI And Disease Reversal The Future of Healthcare: The Role of AI and Technology

Today, we have another episode in our series of thoughtfully curated companies. This episode is sponsored by OneSkin, a company founded and led by an all-female team of PhD-level scientists. OneSkin is redefining how we think about aging, starting with the skin, our largest organ. I am delighted to introduce Dr. Alessandra Zonari as our guest today. Dr. Zonari is far from your typical scientist. She is a true visionary with a passion for longevity, skin regeneration, and an occasional karaoke jam. With degrees in biology and stem cell biology and a doctorate in skin regeneration and tissue engineering, Dr. Zonari brings a wealth of knowledge and a fresh perspective to our conversation today. Join us to learn more about OneSkin and how their products can reverse the effects of biological aging, helping your skin become stronger and more resilient as you age. IN THIS EPISODE YOU WILL LEARN: Dr. Zonari shares her mission to understand how skin can age healthier and stronger and reduce the risk of inflammation and diseases.  How the female-led research team at OneSkin brings a unique perspective to skincare How the OneSkin peptide can reverse 2.5 years of biological aging in just five days The unique way in which they test their products and measure biological aging at OneSkin  How estradiol loss during menopause exacerbates the accumulation of senescent cells and causes inflammation Some common misconceptions about skincare for women in perimenopause and menopause How lifestyle choices influence the aging process of the skin  Why we must protect the skin from environmental stressors to slow the aging process  How your skin cells can get reprogrammed to return to a youthful state How OneSkin developed a hair care line to address hair loss and thinning The importance of self-love and nourishing your body  ABOUT OneSkin:  Founded and led by an all-woman team of PhD-level scientists, OneSkin is transforming the way we think about aging, starting with the body's largest organ, the skin. Our proprietary OS-01 (oh ess one) peptide is the first ingredient to reverse the biological age of skin by targeting cellular senescence, a key driver of aging. By targeting cellular senescence, the OS-01 peptide switches off the damaged cells that contribute to lines, wrinkles, and sagging skin. The result? Skin that looks and behaves younger. Our products are designed for young and mature skin, because it is never too early or too late to invest in your skin health! We create next-level skin care. BIO: Alessandra Zonari, PhD, OneSkin Co-Founder & CSO Alessandra is not your typical scientist. She is a visionary with a passion for longevity, skin regeneration, and the occasional karaoke jam. Growing up in a close-knit family in Brazil, Alessandra saw her grandparents struggle with age-related diseases, and she soon became fascinated by the possibility of using stem cells to redefine the aging process. After earning degrees in biology and stem cell biology and a doctorate in skin regeneration and tissue engineering, Alessandra joined OneSkin in 2017 as a founding member and Chief Scientific Officer. Her contributions include 20+ papers, three patents, and the development of their proprietary OS-01 peptide. Connect with Cynthia Thurlow   Follow on ⁠X⁠ ⁠Instagram⁠ & ⁠LinkedIn⁠ Check out Cynthia's ⁠website⁠ Submit your questions to ⁠support@cynthiathurlow.com⁠ Connect with Dr. Alessandra Zonari On the ONESKIN⁠ website⁠ ONESKIN on⁠ Instagram⁠ Interested in trying OneSkin for yourself? Visit⁠ oneskin.co/CYNTHIA⁠ and use code CYNTHIA for 15% off your first purchase!